ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Return-on-Tangible-Asset : -54.55% (As of Dec. 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset Chart

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.

Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.

ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description